Rucaparib or Physician's Choice in Metastatic Prostate Cancer
Por um escritor misterioso
Descrição
Rucaparib Bests Physician's Choice for BRCA+ mCRPC
Rucaparib Efficacious in Metastatic Castration-Resistant Prostate Cancer - Southern Iowa Mental Health Center
NEJMστο X: Original Article: Rucaparib or Physician's Choice in Metastatic Prostate Cancer (TRITON3) #GU23 #oncology / X
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial - The Lancet Oncology
Rucaparib for Patients with Metastatic Castration-Resistant Prostate Cancer in the TRITON3 Trial – Oliver Sartor
Cancers, Free Full-Text
PARP Inhibition in Metastatic CRPC: The PROfound and TRITON2 Studies
The treatment landscape of metastatic prostate cancer - ScienceDirect
Cancers, Free Full-Text
Current Oncology, Free Full-Text
ASCO GU 2023: Rucaparib for Metastatic Castration-Resistant Prostate Cancer (mCRPC): TRITON3 Interim Overall Survival and Efficacy of Rucaparib vs Docetaxel or Second-Generation Androgen Pathway Inhibitor Therapy
de
por adulto (o preço varia de acordo com o tamanho do grupo)
